The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining a prognostic risk score in ovarian cancer patients by integrated analysis of serum mesothelin, HE4, CA125 and surgical outcome.
 
Pauline Wimberger
Honoraria - Amgen; AstraZeneca; Eisai; MSD Oncology; Novartis/Pfizer; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Amgen; AstraZeneca; MSD Oncology; Novartis; PharmaMar; Roche Pharma AG; Tesaro
Travel, Accommodations, Expenses - Roche Pharma AG
 
Daniel Klotz
Honoraria - Alpha Verlag
Patents, Royalties, Other Intellectual Property - Patent pending: 20 212 397.2; "HGF as a marker for progression of ovarian cancer" (Inst)
 
Maren Göckenjan
No Relationships to Disclose
 
Theresa Link
Honoraria - Amgen; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Eisai; GlaxoSmithKline; Lilly; Myriad Genetic Laboratories; Pfizer; Roche
 
Jan Dominik Kuhlmann
No Relationships to Disclose